ALPL-1 is a target for chimeric antigen receptor therapy in osteosarcoma.

MLA

Mensali, Nadia, et al. “ALPL-1 Is a Target for Chimeric Antigen Receptor Therapy in Osteosarcoma.” Nature Communications, vol. 14, no. 1, June 2023, pp. 1–15. EBSCOhost, https://doi.org/10.1038/s41467-023-39097-x.

APA

Mensali, N., Köksal, H., Joaquina, S., Wernhoff, P., Casey, N. P., Romecin, P., Panisello, C., Rodriguez, R., Vimeux, L., Juzeniene, A., Myhre, M. R., Fåne, A., Ramírez, C. C., Maggadottir, S. M., Duru, A. D., Georgoudaki, A.-M., Grad, I., Maturana, A. D., Gaudernack, G., & Kvalheim, G. (2023). ALPL-1 is a target for chimeric antigen receptor therapy in osteosarcoma. Nature Communications, 14(1), 1–15. https://doi.org/10.1038/s41467-023-39097-x

Chicago

Mensali, Nadia, Hakan Köksal, Sandy Joaquina, Patrik Wernhoff, Nicholas P. Casey, Paola Romecin, Carla Panisello, et al. 2023. “ALPL-1 Is a Target for Chimeric Antigen Receptor Therapy in Osteosarcoma.” Nature Communications 14 (1): 1–15. doi:10.1038/s41467-023-39097-x.